(VERU) Update: Today's Nasdaq Biopharma Profile Is Up Approx. 12% Early!

*Sponsored StockWireNews (VERU) Update: Today's Nasdaq Biopharma Profile Is Up Approx. 12% Early! April 1st Greetings Readers, Veru Inc. (Nasdaq: VERU) continues to reign in the top spot on Tuesday's watchlist. One major reason why is this... VERU has pushed through 4 lines of potential resistance recently. If support grows at these levels, it could create the foundation for VERU to attempt to reach for previous highs. Furthermore, the company shared this announcement Monday: Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference Currently up approx. 12%, (Nasdaq: VERU) could be ready to March highs on the 1st day of April. Take a moment to review my initial report below and consider this Biopharma profile for your radar quickly. ----- Here's an in-depth look at Veru Inc. (Nasdaq: VERU), a biopharmaceutical company at the forefront of developing innovative treatments targeting unmet medical needs in metabolic health, oncology, and other critical therapeutic areas. 6 Immediate Potential Catalysts (Nasdaq: VERU) To Consider: (1.) Industry Growth: The metabolic health market, particularly treatments for obesity, is projected to grow from $46Bn in 2024 to over $470Bn in the next decade, representing a +900% expansion. (2.) Unmet Need: Current metabolic treatments often lead to significant lean muscle loss, posing long-term health risks. Veru Inc. is developing a solution to address this critical gap. (3.) Enobosarm: Veru Inc.'s lead drug candidate, Enobosarm, is a selective androgen receptor modulator (SARM) designed to promote fat reduction while preserving muscle mass. (4.) Promising Clinical Results: Phase 2b clinical trial (QUALITY) results demonstrated that Enobosarm, in combination with metabolic therapies, significantly reduced lean mass loss compared to conventional treatments alone. The Phase 2b extension study results are expected in Q2 2025. (5). Analyst Coverage: Several Wall Street firms (B. Riley Financial ($2), H.C. Wainwright & Co. ($2.50), and Oppenheimer ($4)) have recently reaffirmed their bullish stance on Veru Inc., highlighting significant upside potential. Bill-ionaire healthcare in-vest-or Dr. Phillip Frost has also taken a position in the company. (6.) Potential Market Shift: If approved, Enobosarm could establish a new standard in the metabolic health market by prioritizing muscle preservation, targeted fat reduction, and long-term body composition improvements. ----- Veru's Solution: Enobosarm Veru Inc. is focused on next-generation advancements in body composition and metabolic health. Enobosarm is designed to promote fat reduction while preserving muscle. Phase 2b Trial Results: Patients using Enobosarm alongside metabolic therapy reduced lean mass loss to just 9.4%, with the Enobosarm 3mg group nearly eliminating lean mass loss altogether at just 0.9%. Fat Reduction: An estimated 90.6% of total reduction came from fat, and for the Enobosarm 3mg group, that number soared to 99.1%—virtually pure fat loss. Physical Function Improvements: Patients using Enobosarm alongside metabolic therapy saw a 62.4% reduction in significant (>10%) stair climb power loss. Market Opp. and Future Outlook: Veru Inc. is moving toward a pivotal Phase 3 trial. With millions of people using current metabolic therapies and no FDA-approved solution to protect muscle mass, Veru Inc. (Nasdaq: VERU) could be at the center of one of the most critical innovations in body composition and metabolic health. Management Team: Veru Inc. is led by an experienced management team with expertise in drug development, regulatory affairs, and corporate strategy. Dr. Mitchell Steiner (CEO): Decades of experience in urology, oncology, and pharmaceutical leadership. Dr. Etan Fisch (Co-founder): Expertise in urology and reproductive medicine. Dr. Gary Barnette (Chief Regulatory Officer): Extensive regulatory and clinical development experience, including time at the FDA. ----- Recap: 6 Potential Catalysts To Consider For (Nasdaq: VERU) (1). The Metabolic Health Market Is Projected To Expand From $46Bn In 2024 To Over $470Bn Within A Decade, Representing +900% Growth. (2.) Current Treatments Often Cause Lean Muscle Loss, But Veru Inc. Is Developing A Solution To Address This Critical Gap. (3.) Enobosarm Is A Selective Androgen Receptor Modulator Designed To Reduce Fat While Preserving Muscle Mass. (4.) Phase 2b Clinical Trials Showed Enobosarm Significantly Reduced Lean Muscle Loss Compared To Conventional Treatments, With Extension Results Expected In Q2 2025. (5.) Wall Street Firms And Bill-ion-aire In-vest-or Have Expressed Confidence In Veru Inc.'s Upside Potential. (6.) If Approved, Enobosarm Could Transform The Metabolic Health Market By Setting A New Standard For Muscle Preservation And Fat Reduction. ----- Veru Inc. (Nasdaq: VERU) presents a compelling watchlist opp. within the rapidly growing metabolic health market. Its novel approach to preserving muscle mass during wei-ght loss, combined with promising clinical results and growing industry attention, positions the company for strong success potential. Coverage is officially initiated on Veru Inc. (Nasdaq: VERU). I'll be in touch with updates soon. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) Unsubscribe Stock Wire News 160 West Camino Real Unit 886 Boca Raton, Florida 33432 United States